Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 56.20% is 46% above its 1-year average of 38.58%, near the high end of its 1-year range (0.00%–60.21%).
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 60.21%.
GROSS MARGIN
56.20%
GROSS MARGIN AVG TTM
N/A
GROSS MARGIN AVG 3Y
N/A
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.92%
median of 567 covered companies
CURRENT VS SECTOR MEDIAN
+30.94%
vs the sector median at left
Market Cap
$2.59B
Gross Margin
92.15%
TTM Avg
99.87%
3Y Avg
99.94%
5Y Avg
66.62%
Market Cap
$2.60B
Gross Margin
84.05%
TTM Avg
-197.31%
3Y Avg
-176.53%
5Y Avg
-71811.06%
Market Cap
$2.45B
Gross Margin
92.48%
TTM Avg
74.82%
3Y Avg
78.80%
5Y Avg
76.59%
Market Cap
$2.40B
Gross Margin
18.57%
TTM Avg
22.55%
3Y Avg
18.71%
5Y Avg
13.63%
Market Cap
$2.40B
Gross Margin
-61.96%
TTM Avg
-19.42%
3Y Avg
-14.39%
5Y Avg
23.74%
Market Cap
$2.67B
Gross Margin
17.61%
TTM Avg
20.09%
3Y Avg
39.91%
5Y Avg
58.59%
Market Cap
$2.71B
Gross Margin
31.95%
TTM Avg
33.09%
3Y Avg
31.97%
5Y Avg
31.83%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alamar Biosciences, Inc. (ALMR) | $2.52B | 56.20% | N/A | N/A | N/A |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.59B | 92.15% | 99.87% | 99.94% | 66.62% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.60B | 84.05% | -197.31% | -176.53% | -71811.06% |
| Liquidia Corporation (LQDA)vs › | $2.45B | 92.48% | 74.82% | 78.80% | 76.59% |
| Disc Medicine, Inc. (IRON)vs › | $2.44B | 0.00% | 0.00% | 0.00% | 0.00% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | 18.57% | 22.55% | 18.71% | 13.63% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.40B | -61.96% | -19.42% | -14.39% | 23.74% |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.67B | 17.61% | 20.09% | 39.91% | 58.59% |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.71B | 31.95% | 33.09% | 31.97% | 31.83% |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.71B | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
56.2%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 60.21% |
| 2026-03-31 | 55.53% |
| 2025-12-31 | 0.00% |
